Matches in SemOpenAlex for { <https://semopenalex.org/work/W1459949752> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W1459949752 endingPage "5518" @default.
- W1459949752 startingPage "5518" @default.
- W1459949752 abstract "We recently reported that Fanconi Anemia (FA)/BRCA DNA damage repair pathway genes are overexpressed and causative for resistance in multiple myeloma (MM) cell lines selected for resistance to melphalan (Chen et al., Blood 2005). Furthermore, others have found that proteasome function is required for FA/BRCA pathway activation (Jacquemont et al., Cancer Res 2007). In this study, we show that the enhanced sensitivity to melphalan seen when cells are first treated with bortezomib is linked to reduced expression and function of FA/BRCA pathway genes. We found that treatment of melphalan sensitive (8226/S and U266/S) and melphalan resistant (8226/LR5 and U266/LR6) MM cell lines with the proteasome inhibitor bortezomib causes a temporal decrease of FA/BRCA pathway gene expression, with maximal decreases seen 24 hours post-bortezomib treatment. Additionally, analysis of two drug resistant MM cell lines, the 8226/LR5 and U266/LR6 cell lines, revealed that FANCD2 gene and protein expression were decreased following treatment with low-dose (3nM) bortezomib, and remain attenuated with the combination of bortezomib plus melphalan. Bortezomib blocked melphalan-induced activation of FANCD2 in both melphalan resistant cell lines, as indicated by inhibition of monoubiquitination of FANCD2 protein. Using confocal microscopy, we found that melphalan-induced FANCD2 foci formation was also inhibited by bortezomib. Analysis of DNA damage and DNA damage repair, using the alkaline comet assay following treatment with low-dose bortezomib and melphalan, showed that bortezomib enhanced DNA damage following melphalan treatment at levels comparable to DNA damage seen when cells were depleted of FANCD2 using siRNA techniques. Collectively, these data show that bortezomib enhances melphalan response by reducing global FA/BRCA gene expression, blocking FANCD2 monoubiquitination and activation, and enhancing DNA damage, secondary to diminished DNA damage repair capacity mediated by the FA/BRCA pathway. Our findings provide evidence for targeting the FA/BRCA pathway to enhance chemotherapeutic response and reverse drug resistance in multiple myeloma patients. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5518." @default.
- W1459949752 created "2016-06-24" @default.
- W1459949752 creator A5000451156 @default.
- W1459949752 creator A5032654984 @default.
- W1459949752 creator A5033112541 @default.
- W1459949752 creator A5054463097 @default.
- W1459949752 creator A5056492087 @default.
- W1459949752 creator A5069218667 @default.
- W1459949752 creator A5071565523 @default.
- W1459949752 creator A5087985396 @default.
- W1459949752 date "2009-05-01" @default.
- W1459949752 modified "2023-09-23" @default.
- W1459949752 title "Abstract #5518: Bortezomib targets FANCD2 and enhances melphalan response in myeloma cells" @default.
- W1459949752 hasPublicationYear "2009" @default.
- W1459949752 type Work @default.
- W1459949752 sameAs 1459949752 @default.
- W1459949752 citedByCount "0" @default.
- W1459949752 crossrefType "journal-article" @default.
- W1459949752 hasAuthorship W1459949752A5000451156 @default.
- W1459949752 hasAuthorship W1459949752A5032654984 @default.
- W1459949752 hasAuthorship W1459949752A5033112541 @default.
- W1459949752 hasAuthorship W1459949752A5054463097 @default.
- W1459949752 hasAuthorship W1459949752A5056492087 @default.
- W1459949752 hasAuthorship W1459949752A5069218667 @default.
- W1459949752 hasAuthorship W1459949752A5071565523 @default.
- W1459949752 hasAuthorship W1459949752A5087985396 @default.
- W1459949752 hasConcept C134935766 @default.
- W1459949752 hasConcept C143425029 @default.
- W1459949752 hasConcept C153911025 @default.
- W1459949752 hasConcept C203014093 @default.
- W1459949752 hasConcept C2776364478 @default.
- W1459949752 hasConcept C2776653068 @default.
- W1459949752 hasConcept C2777478702 @default.
- W1459949752 hasConcept C2778124228 @default.
- W1459949752 hasConcept C2778367456 @default.
- W1459949752 hasConcept C2778684742 @default.
- W1459949752 hasConcept C502942594 @default.
- W1459949752 hasConcept C552990157 @default.
- W1459949752 hasConcept C55493867 @default.
- W1459949752 hasConcept C86803240 @default.
- W1459949752 hasConceptScore W1459949752C134935766 @default.
- W1459949752 hasConceptScore W1459949752C143425029 @default.
- W1459949752 hasConceptScore W1459949752C153911025 @default.
- W1459949752 hasConceptScore W1459949752C203014093 @default.
- W1459949752 hasConceptScore W1459949752C2776364478 @default.
- W1459949752 hasConceptScore W1459949752C2776653068 @default.
- W1459949752 hasConceptScore W1459949752C2777478702 @default.
- W1459949752 hasConceptScore W1459949752C2778124228 @default.
- W1459949752 hasConceptScore W1459949752C2778367456 @default.
- W1459949752 hasConceptScore W1459949752C2778684742 @default.
- W1459949752 hasConceptScore W1459949752C502942594 @default.
- W1459949752 hasConceptScore W1459949752C552990157 @default.
- W1459949752 hasConceptScore W1459949752C55493867 @default.
- W1459949752 hasConceptScore W1459949752C86803240 @default.
- W1459949752 hasLocation W14599497521 @default.
- W1459949752 hasOpenAccess W1459949752 @default.
- W1459949752 hasPrimaryLocation W14599497521 @default.
- W1459949752 hasRelatedWork W1988390558 @default.
- W1459949752 hasRelatedWork W2000878523 @default.
- W1459949752 hasRelatedWork W2059911857 @default.
- W1459949752 hasRelatedWork W2167668181 @default.
- W1459949752 hasRelatedWork W2318717008 @default.
- W1459949752 hasRelatedWork W2322708681 @default.
- W1459949752 hasRelatedWork W2530134230 @default.
- W1459949752 hasRelatedWork W2555354504 @default.
- W1459949752 hasRelatedWork W2556085825 @default.
- W1459949752 hasRelatedWork W2563013089 @default.
- W1459949752 hasRelatedWork W2566244553 @default.
- W1459949752 hasRelatedWork W2580497187 @default.
- W1459949752 hasRelatedWork W2586311056 @default.
- W1459949752 hasRelatedWork W2586801941 @default.
- W1459949752 hasRelatedWork W2730285790 @default.
- W1459949752 hasRelatedWork W2767055716 @default.
- W1459949752 hasRelatedWork W2922858893 @default.
- W1459949752 hasRelatedWork W2978674210 @default.
- W1459949752 hasRelatedWork W2992223253 @default.
- W1459949752 hasRelatedWork W303134721 @default.
- W1459949752 hasVolume "69" @default.
- W1459949752 isParatext "false" @default.
- W1459949752 isRetracted "false" @default.
- W1459949752 magId "1459949752" @default.
- W1459949752 workType "article" @default.